Key facts
- CytoTronics’s last known valuation is $39.0M.
- It has raised $22.8M across 1 recorded rounds; the latest was Early Stage VC ($13.5M) in Mar 2024.
- Notable investors include Draper Associates, Legend Star, Bantam Group, BoxOne Ventures, Harvard University — 9 tracked in total.
- CytoTronics has filed 1 Form D with the SEC, most recently Oct 2024 ($13.5M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CytoTronics
Funding rounds
1 roundsAbout CytoTronics
Developer of semiconductor-based systems designed for studying cell biology. The company's technology allows researchers to visualize live cell function at scale and gain real-time data on cell behavior, enabling researchers to study complex biological processes in greater detail, potentially leading to breakthroughs in areas like drug discovery and personalized medicine.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2020
- Employees
- 32
- Website
- cytotronics.com/
- Ownership
- Privately Held (backing)
CytoTronics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CytoTronics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CytoTronics in its N-PORT filings yet. We sweep new filings monthly.